At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Fulvestrant +1 moredrug
Likely dose
Anastrozole 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised Phase II Study Comparing Anastrozole and Fulvestrant to Anastrozole for Adjuvant Treatment of Postmenopausal Patients With Early Breast Cancer and Disseminated Tumour Cells in Bone Marrow
In Brief
A Phase 2 clinical trial evaluating Fulvestrant and Anastrozole for Breast Cancer. Completed, enrolled 13 participants across 25 sites in 3 countries.
Detailed Summary
Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients with early breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesAustria, Germany, Norway
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedJul 2006
Primary CompletionOct 2008
TodayJul 2026
First PostedJul 27, 2006
Enrollment StartApr 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.9 years ago
Interventions
Fulvestrantdrug
intramuscular injection
Anastrozoledrug
1 mg oral tablet